Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nevirapine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A1 | NO_INTERVENTION | - |
| A2 | EXPERIMENTAL | - |
| A3 | EXPERIMENTAL | - |
| B1 | NO_INTERVENTION | - |
| Name | Type | Description |
|---|---|---|
| Nevirapine | DRUG | Tablets, Oral, 200 mg, Twice daily, 3 days. |
| Nevirapine + Atazanavir/Ritonavir | DRUG | Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days. |
| Atazanavir + Ritonavir | DRUG | Capsules/capsules, Oral, 300/100 mg, once daily, 10 days. |
Inclusion Criteria: * signed informed consent form * For Cohort 1, HIV-infected subjects receiving nevirapine 200 mg twice-daily and 2 to 3 NRTIs for at least 6 weeks * For Cohort 2, HIV-infected subjects receiving atazanavir 300 mg and ritonavir 100 mg once-daily and 2 to 3 NRTIs for at least 6 we...
Top 20 of 28 competitors
Nevirapine is a small molecule drug being studied for the treatment of HIV Infections. It is currently in Phase 1 clinical development as an investigational therapy. The drug is being evaluated in a clinical trial to assess its interaction with other antiretroviral medications in patients with HIV.
Nevirapine is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical research to evaluate the drug's safety and pharmacokinetics in the context of HIV treatment.
Nevirapine is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the treatment of HIV Infections. The Phase 1 trial has been completed, and the drug remains under evaluation for its potential use in HIV therapy.
Nevirapine has one completed clinical trial registered under NCT00162149, titled 'ATV/Ritonavir Nevirapine Interaction (USPAC)'. This Phase 1 study enrolled 46 participants with HIV Infections and was conducted in the United States and United Kingdom. The trial was not randomized or double-blinded and used a no-treatment control.
Nevirapine is a small molecule drug being investigated for HIV Infections. As a non-nucleoside reverse transcriptase inhibitor, it works by binding to and inhibiting the reverse transcriptase enzyme, which is essential for HIV replication. This mechanism helps reduce viral load in infected individuals.